Terns Pharmaceuticals Future Growth
Future criteria checks 0/6
Terns Pharmaceuticals's revenue and earnings are forecast to decline at 46.1% and 19.1% per annum respectively. EPS is expected to grow by 4.4% per annum. Return on equity is forecast to be -36.3% in 3 years.
Key information
-19.1%
Earnings growth rate
4.4%
EPS growth rate
Pharmaceuticals earnings growth | 22.2% |
Revenue growth rate | -46.1% |
Future return on equity | -36.3% |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | N/A | -92 | -77 | -76 | 3 |
12/31/2023 | N/A | -80 | -58 | -58 | 3 |
12/31/2022 | N/A | -63 | -33 | -33 | 3 |
9/30/2022 | 1 | -59 | -49 | -49 | N/A |
6/30/2022 | 1 | -54 | -44 | -43 | N/A |
3/31/2022 | 1 | -51 | -41 | -41 | N/A |
12/31/2021 | 1 | -50 | -42 | -42 | N/A |
9/30/2021 | N/A | -35 | -39 | -39 | N/A |
6/30/2021 | N/A | -35 | -37 | -37 | N/A |
3/31/2021 | N/A | -34 | -37 | -37 | N/A |
12/31/2020 | N/A | -29 | -30 | -30 | N/A |
9/30/2020 | N/A | -40 | -33 | -32 | N/A |
12/31/2019 | N/A | -69 | -67 | -66 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 430 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 430 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 430 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 430 is forecast to have no revenue next year.
High Growth Revenue: 430 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 430 is forecast to be unprofitable in 3 years.